.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Teva
Queensland Health
UBS
Deloitte
Colorcon
Citi
QuintilesIMS
Farmers Insurance
Chinese Patent Office

Generated: June 22, 2017

DrugPatentWatch Database Preview

DILAUDID-HP Drug Profile

« Back to Dashboard

What is the patent landscape for Dilaudid-hp, and when can generic versions of Dilaudid-hp launch?

Dilaudid-hp is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in nine countries.

The generic ingredient in DILAUDID-HP is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

Summary for Tradename: DILAUDID-HP

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list8
Clinical Trials: see list43
Patent Applications: see list4,786
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DILAUDID-HP at DailyMed

Pharmacology for Tradename: DILAUDID-HP

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-001Jan 11, 1984APRXYesYes6,589,960► SubscribeY ► Subscribe
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-002Aug 4, 1994DISCNNoNo6,589,960► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DILAUDID-HP

Drugname Dosage Strength RLD Submissiondate
hydromorphone hydrochlorideInjection10 mg/mLDilaudid-HP11/4/2011

Non-Orange Book Patents for Tradename: DILAUDID-HP

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DILAUDID-HP

Country Document Number Estimated Expiration
Austria402937► Subscribe
Canada2854796► Subscribe
European Patent Office2003134► Subscribe
Spain2359657► Subscribe
Japan4886953► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
QuintilesIMS
Dow
Merck
Colorcon
Johnson and Johnson
Queensland Health
Mallinckrodt
Teva
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot